Zoladex (goserelin acetate) and the anemic patient: results of a multicenter fibroid study

To compare the effects of goserelin acetate treatment with or without iron with iron alone. Multinational, multicenter, prospective, randomized, double-blind study. Premenopausal women with menorrhagia or metrorrhagia and anemia associated with uterine leiomyomata awaiting hysterectomy. Patients were randomized to one of three 12-week treatment groups namely goserelin acetate 3.6mg once monthly plus placebo iron; 3.6mg goserelin acetate once monthly plus 600mg/d iron; or sham injection once monthly plus 600mg/d iron. Preoperative hemoglobin concentration; preoperative uterine and fibroid volumes and operative blood loss. Considering the entry and preoperative hemoglobin concentrations, there was a difference in least square means of just over 1g/dL between the goserelin acetate plus iron and iron only groups and 2.6g/dL between the goserelin acetate plus iron and goserelin acetate only group. These differences were both statistically significant. Uterine and fibroid volumes were decreased in the goserelin acetate-treated patients by between 37% and 40% and 44% and 47%, respectively, compared with 7% decreases for both in the iron only group. The differences in absolute changes were statistically significant for both the goserelin acetate-treated groups versus the iron-treated group. The least square geometric mean operative blood loss was greatest in the iron only group. In the patient with uterine leiomyomata and anemia, goserelin acetate in combination with iron therapy has shown significant advantages over iron alone in restoring hematologic normality, decreasing uterine and fibroid volumes, and reducing operative blood loss.